Physician profile
Duane P Pool
NPI 1073599031
$3,917.52
in general payments reported to CMS, 2019-2025
33 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $349 · 2021: $327 · 2022: $337 · 2023: $524 · 2024: $845 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $594.09 | 2019-2025 | Watchman Flx, Cds - Other, Bodyguardian |
| Amgen INC. | $546.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $525.62 | 2020-2025 | |
| Pfizer INC. | $504.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $231.02 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $166.58 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Edwards Lifesciences Corporation | $146.14 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Esperion Therapeutics, INC. | $144.23 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $104.66 | 2019-2023 | |
| Abiomed | $90.25 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $80.00 | 2021-2022 | |
| Veryan Medical Incorporated | $74.29 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.14 | 2019-2022 | |
| Novo Nordisk INC | $69.93 | 2023-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $67.80 | 2022-2024 | Mitraclip |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $51.64 | 2024-2025 | |
| Altathera Pharmaceuticals LLC | $43.79 | 2024-2025 | Sotalol Hydrochloride |
| Medtronic Vascular, INC. | $37.22 | 2019-2020 | |
| Amarin Pharma, INC. | $35.58 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $34.80 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.92 | 2020-2025 | Jardiance |
| American Regent | $32.84 | 2023-2024 | Injectafer |
| Cvrx, INC. | $32.80 | 2023-2025 | Barostim Neo System |
| Atricure, INC. | $28.25 | 2023 | |
| Merck Sharp & Dohme LLC | $25.28 | 2025 | Verquvo |
| Octapharma USA, INC. | $24.29 | 2025 | Fibryga |
| Lexicon Pharmaceuticals, INC. | $23.62 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.84 | 2020 | |
| Medtronic, INC. | $18.24 | 2025 | Symplicity G3 |
| Actelion Pharmaceuticals US, INC. | $17.54 | 2024 | Uptravi, Opsumit |
| W. L. Gore & Associates, INC. | $15.08 | 2025 | Gore Cardioform Septal Occluder |
| Daiichi Sankyo INC. | $14.80 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Pool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.